Development of α-Gal-Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies

Angew Chem Int Ed Engl. 2019 Mar 26;58(14):4526-4530. doi: 10.1002/anie.201812914. Epub 2019 Mar 8.

Abstract

Cancer treatment with antibodies (Abs) is one of the most successful therapeutic strategies for obtaining high selectivity. In this study, α-gal-Ab conjugates were developed that dramatically increased cellular cytotoxicity by recruiting natural Abs through the interaction between α-gal and anti-gal Abs. The potency of the α-gal-Ab conjugates depended on the amount of α-gal conjugated to the antibody: the larger the amount of α-gal introduced, the higher the level of cytotoxicity observed. The conjugation of antibodies with an α-gal dendrimer allowed the introduction of large amounts of α-gal to the Ab, without loss of affinity for the target cell. The method described here will enable the re-development of Abs to improve their potency.

Keywords: antibody-drug conjugates; dendrimer; immunotherapy; α-gal epitope.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / chemistry
  • Antibodies / immunology*
  • Carbohydrate Conformation
  • Cell Line, Tumor
  • Cell Survival / immunology
  • Humans
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Neoplasms / therapy
  • Trisaccharides / chemical synthesis
  • Trisaccharides / chemistry
  • Trisaccharides / immunology*

Substances

  • Antibodies
  • Trisaccharides
  • alpha-galactosyl epitope